announces

Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel)

CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene…

4 months ago

LRS Output Management Announces Cloud-Based Print, Scan, and Auditing Suite

Solutions leverage proven LRS Mission Control platform SPRINGFIELD, Ill., Oct. 30, 2025 /PRNewswire/ -- Levi, Ray & Shoup, Inc. (LRS) today…

4 months ago

NOBU HOSPITALITY ANNOUNCES FIRST NOBU LUXURY SERVICED RESIDENCES AND RESTAURANT IN KUWAIT

NEW YORK, Oct. 30, 2025 /PRNewswire/ -- Nobu Hospitality, the global lifestyle brand proudly announces its partnership with United Real Estate…

4 months ago

ROCK & ROLL HALL OF FAME ANNOUNCES ADDITIONAL PRESENTERS AND PERFORMERS FOR 2025 INDUCTION CEREMONY

More Stars Join the Celebration of Music's Highest Honor, Streaming Live on Disney+ Saturday, Nov. 8 NEW YORK, Oct. 29,…

4 months ago

Tenable Announces Third Quarter 2025 Financial Results

Tenable Exceeds Q3 Revenue and Profit Expectations, Raises Full-Year Outlook Revenue of $252.4 million, year-over-year growth of 11%Calculated current billings…

4 months ago

Armada Acquisition Corp. II Announces Ticker Symbol to Change to XRPN on Oct 30, 2025

New ticker aligns with new $1 billion strategy for XRP exposure on NASDAQ MIAMI, Oct. 29, 2025 /PRNewswire/ -- Armada Acquisition…

4 months ago

Supermicro Announces U.S Federal Entity to Expand Further into the Federal Market — Extensive US-Based Manufacturing of AI Server Portfolio Targets the Federal Ecosystem

Delivers AI-optimized infrastructure, and energy-efficient computing systems, from the largest design and manufacturing facility in Silicon Valley, California Continued growth…

4 months ago

Varonis Announces $150 Million Share Repurchase Authorization

October 28, 2025 16:05 ET  | Source: Varonis Systems, Inc. MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc.…

4 months ago

Varonis Announces Third Quarter 2025 Financial Results

Annual recurring revenues increased 18% year-over-yearSaaS ARR as a percentage of total ARR was approximately 76%Year-to-date cash from operations generated…

4 months ago

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…

4 months ago